Reddit Emerges as a Major Winner in the Shift to AI-Powered Search 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
U.S. Airline Flight Cancellations Surge After Venezuela Military Operation and FAA Airspace Closures 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Tesla Poised for Breakout Year in 2026 as New Products and EV Market Reset Drive Growth 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
NEW YORK, April 04, 2016 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 15th Annual Needham Healthcare Conference in New York. The presentation is scheduled for Tuesday, April 12, 2016 at 4:20 p.m. EDT.
The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.
Contact: Juan Sanchez, M.D. Vice President Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. Phone: 212-923-3344 Burns McClellan, Inc. Lisa Burns Justin Jackson (Media) [email protected] 212-213-0006
